Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | PAICS | P22234 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | WNT1 | P04628 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018120 | 0.93 | BRD4 (0.51) | BRD4TTKNAMPTGSK3BDYRK1A | |
| SCHEMBL17018269 | 0.93 | BRD4 (0.47) | BRD4TTKCTSKCTSC | |
| SCHEMBL17018270 | 0.92 | BRD4 (0.59) | BRD4TTK | |
| SCHEMBL17018249 | 0.92 | BRD4 (0.49) | BRD4TTKGSK3BDYRK1A | |
| SCHEMBL17018263 | 0.91 | BRD4 (0.54) | BRD4TTKCTSKCTSC | |
| SCHEMBL21249959 | 0.90 | BRD4 (0.47) | BRD4GSK3BDYRK1A | |
| SCHEMBL17018258 | 0.89 | BRD4 (0.47) | BRD4TTKGSK3BDYRK1A | |
| SCHEMBL17018283 | 0.88 | BRD4 (0.46) | BRD4GSK3BDYRK1A | |
| SCHEMBL17018282 | 0.88 | BRD4 (0.46) | BRD4GSK3BDYRK1A | |
| SCHEMBL17018118 | 0.88 | BRD4 (0.52) | BRD4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TTK 4015/4885PAICS 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.